Month: August 2022

Icelandair: Date of Transaction – 15 August 2022

Written by Customer Service on August 15, 2022. Posted in Public Companies.

Attached is information regarding a transaction conducted by a person discharging managerial responsibilities in relation to the exercise of warrants ICEAIRW120822. Contact information Investors: Iris Hulda Thorisdottir, Director Investor Relations. E-mail: iris@icelandairgroup.is Media: Asdis Petursdottir, Director Communications. E-mail: asdis@icelandair.isAttachments220815 – PDMR Transaction – Sylvia Kristin220815 – Viðskipta stjórnanda – Sylvía Kristín

Flöggun Kvika eignastýring

Written by Customer Service on August 15, 2022. Posted in Public Companies.

Sjá meðfylgjandi tilkynningu um flöggun frá Kviku eignastýringuAttachmentFlöggun Nova Kvika banki hf

Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID

Written by Customer Service on August 15, 2022. Posted in Public Companies.

New York, NY, and Tel Aviv, ISRAEL, Aug. 15, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of a case study entitled “COVID-19 Vaccines are Necessary but not Sufficient”, overseen by Dr. Lee Morgentaler in concert with Andrew A. Blumenthal, RN ADS of two patients with Post-Acute Sequelae of COVID (PASC, or “Long COVID”) who experienced limited benefit after vaccination, who subsequently experienced significant benefit after supplementation with 3CL protease inhibitor immune support supplement Tollovid™. The pre-publication can be viewed at: https://www.researchgate.net/publication/362694094_A_Case_Review_COVID-19_Vaccines_are_Necessary_but_not_Sufficient. ABSTRACTMessenger...

Salona Global Announces LOI to Acquire $26M Annual Revenue Medical Device Company, Executes Binding Agreement to Acquire DaMar Plastics with $6.38M in Annual Revenue

Written by Customer Service on August 15, 2022. Posted in Mergers And Acquisitions.

SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (“Salona Global,” “SGMD,” or the ‎‎“Company”) (TSXV:SGMD) has executed a non-binding letter of intent (“LOI”) dated August 11, 2022 to acquire rehabilitation and sports medicine device assets (“Acquisition Target”) that have unaudited annual revenues of $26 million with gross margins in excess of 30%. Additionally, the Company executed a definitive agreement (the “Purchase Agreement”) to acquire DaMar Plastics Manufacturing, Inc. (“DaMar Plastics”), a $6.38 million in annual revenue plastics business with 47% gross profits. If both acquisitions are closed as management plans, SGMD revenues are set to increase more than 60% from the existing reported $47,900,000 annualized run rate revenue in May 2022 and gross margins would remain between 30-36%....

Sigyn Therapeutics Announces Second Quarter 2022 Financial Results

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

SAN DIEGO, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address unmet needs in global health, today announces its financial results for the second quarter ended June 30, 2022 and provides an update on recent corporate developments. “We continue to take meaningful steps toward our goal to advance Sigyn Therapy into human clinical studies,” commented Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Of particular note was our successful completion of in vivo animal studies, which followed a series of in vitro studies that demonstrated the ability of Sigyn Therapy to isolate and extract pathogen sources of life-threatening inflammation in concert with the broad-spectrum depletion of proinflammatory...

Stryve Foods, Inc. Reports Fiscal 2022 Second Quarter Results

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

Record Second Quarter Revenue – Full Year Revenue Guidance of $35M to $37M New Leadership Restructuring with Expected Profit Inflection During First Half 2023 Positioned for New Debt Financing Including Over $20M Non-Dilutive Borrowing Capacity PLANO, Texas, Aug. 15, 2022 (GLOBE NEWSWIRE) — Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (CPG) categories, and a leader in the air-dried meat snack industry in the United States, today reports financial and operating results for the three and six months ended June 30, 2022. Chris Boever, Chief Executive Officer, commented, “The record revenue quarter, although challenging, demonstrated a growing consumer demand of the better for you, air dried meat snack category, as well...

Galaxy Gaming Reports Q2 2022 Financial Results

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

LAS VEGAS, Aug. 15, 2022 (GLOBE NEWSWIRE) — Galaxy Gaming, Inc. (OTCQB: GLXZ), a developer and distributor of casino table games and enhanced systems for land-based casinos and iGaming content, announced today its financial results for the quarter and six months June 30, 2022. Financial Highlights Q2 2022 vs. Q2 2021Revenue increased 20% to $5,676K Adjusted EBITDA increased 10% to $2,358K Net loss of $(1,116)K vs. net income of 550K1H 2022 vs. 1H 2021Revenue increased 28% to $11,595K Adjusted EBITDA increased 31% to $5,032K Net loss of $(1,130)K vs. net income of 639KBalance Sheet Changes (vs. December 31, 2021)Cash increased 7% to $17,250K Total long-term debt1 (gross) decreased to $59,868K from $60,500K Stockholders’ deficit increased to $(18,0297)K from $(17,286)KExecutive Comments “The second quarter of 2022 was...

Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

Quarter marked by initiation of Phase 3 study evaluating LB1148 for postoperative return of bowel function CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — Palisade Bio (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company”), reported its financial results for the quarter ended June 30, 2022. Additionally, the Company provided a clinical program update for its lead asset in development, LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Recent HighlightsEntered into an underwriting agreement on August 12, 2022 for public offering for expected gross proceeds of $12 million, bringing total equity funding to...

FOMO CORP. ANNOUNCES RECORD QUARTER; POSITIONED FOR ACCELERATED GROWTH

Written by Customer Service on August 15, 2022. Posted in Public Companies.

Chicago IL, Aug. 15, 2022 (GLOBE NEWSWIRE) — FOMO CORP. (US OTC: FOMC) announces record second quarter results driven by significant demand for interactive whiteboard and EdTech solutions from K12 schools in Ohio, Pennsylvania, and West Virginia. Additionally, the Company positioned its clean tech business for renewed growth and continued to explore strategic mergers, acquisitions and investments. Strong 2Q22 Results Illustrate Inflection Point in the Business In the second quarter ended June 30, 2022, on a consolidated basis, the Company generated revenues of $2.6 million up $2.515 million or 2,959% from $85,000 during the same period in 2021. During the six months ended June 30, 2022, on a consolidated basis, the Company generated $3.9 million top line, up $3.65 million or 1,460% from $250,000 during the prior year’s same period....

InterCure Reports Record Breaking Second Quarter Financial Results

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

Rapid Revenue and EBITDA Growth Rapid Revenue and EBITDA Growth by Half Year CAD millionsRecord revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAiifor Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (“InterCure” or the “Company”) is pleased to announce its financial results for the second quarter of 2022 and is pleased to provide shareholders...

Month: August 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals